Medical Care
Global Malignant Mesothelioma Therapeutic Market Research Report 2024
- Feb 19, 24
- ID: 58346
- Pages: 83
- Figures: 172
- Views: 20
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The global Malignant Mesothelioma Therapeutic market was valued at US$ 329.8 million in 2023 and is anticipated to reach US$ 532.5 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Report Scope
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Mesothelioma Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The global Malignant Mesothelioma Therapeutic market was valued at US$ 329.8 million in 2023 and is anticipated to reach US$ 532.5 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Report Scope
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Mesothelioma Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2019-2030)
2.2 Malignant Mesothelioma Therapeutic Growth Trends by Region
2.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Malignant Mesothelioma Therapeutic Market Dynamics
2.3.1 Malignant Mesothelioma Therapeutic Industry Trends
2.3.2 Malignant Mesothelioma Therapeutic Market Drivers
2.3.3 Malignant Mesothelioma Therapeutic Market Challenges
2.3.4 Malignant Mesothelioma Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2023
3.5 Malignant Mesothelioma Therapeutic Key Players Head office and Area Served
3.6 Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
3.7 Date of Enter into Malignant Mesothelioma Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
6.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2019-2030)
7.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
9.2 Latin America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Detail
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Detail
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Detail
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.11.5 Sun Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2019-2030)
2.2 Malignant Mesothelioma Therapeutic Growth Trends by Region
2.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Malignant Mesothelioma Therapeutic Market Dynamics
2.3.1 Malignant Mesothelioma Therapeutic Industry Trends
2.3.2 Malignant Mesothelioma Therapeutic Market Drivers
2.3.3 Malignant Mesothelioma Therapeutic Market Challenges
2.3.4 Malignant Mesothelioma Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2023
3.5 Malignant Mesothelioma Therapeutic Key Players Head office and Area Served
3.6 Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
3.7 Date of Enter into Malignant Mesothelioma Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
6.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2019-2030)
7.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
9.2 Latin America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Detail
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Detail
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Detail
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.11.5 Sun Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Pemetrexed
Table 3. Key Players of Cisplatin
Table 4. Key Players of Others
Table 5. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Malignant Mesothelioma Therapeutic Market Share by Region (2019-2024)
Table 9. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Malignant Mesothelioma Therapeutic Market Share by Region (2025-2030)
Table 11. Malignant Mesothelioma Therapeutic Market Trends
Table 12. Malignant Mesothelioma Therapeutic Market Drivers
Table 13. Malignant Mesothelioma Therapeutic Market Challenges
Table 14. Malignant Mesothelioma Therapeutic Market Restraints
Table 15. Global Malignant Mesothelioma Therapeutic Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Malignant Mesothelioma Therapeutic Market Share by Players (2019-2024)
Table 17. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)
Table 18. Ranking of Global Top Malignant Mesothelioma Therapeutic Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
Table 22. Date of Enter into Malignant Mesothelioma Therapeutic Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2024)
Table 26. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2025-2030)
Table 28. Global Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019-2024)
Table 30. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2025-2030)
Table 32. North America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 47. Eli Lilly Company Detail
Table 48. Eli Lilly Business Overview
Table 49. Eli Lilly Malignant Mesothelioma Therapeutic Product
Table 50. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 51. Eli Lilly Recent Development
Table 52. Teva Company Detail
Table 53. Teva Business Overview
Table 54. Teva Malignant Mesothelioma Therapeutic Product
Table 55. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 56. Teva Recent Development
Table 57. Sanofi Company Detail
Table 58. Sanofi Business Overview
Table 59. Sanofi Malignant Mesothelioma Therapeutic Product
Table 60. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 61. Sanofi Recent Development
Table 62. Bristol-Myers Squibb Company Detail
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product
Table 65. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Malignant Mesothelioma Therapeutic Product
Table 70. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Roche Company Detail
Table 73. Roche Business Overview
Table 74. Roche Malignant Mesothelioma Therapeutic Product
Table 75. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 76. Roche Recent Development
Table 77. Merck Company Detail
Table 78. Merck Business Overview
Table 79. Merck Malignant Mesothelioma Therapeutic Product
Table 80. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 81. Merck Recent Development
Table 82. Ono Pharmaceutical Company Detail
Table 83. Ono Pharmaceutical Business Overview
Table 84. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product
Table 85. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 86. Ono Pharmaceutical Recent Development
Table 87. Mylan Company Detail
Table 88. Mylan Business Overview
Table 89. Mylan Malignant Mesothelioma Therapeutic Product
Table 90. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 91. Mylan Recent Development
Table 92. Fresenius Kabi Company Detail
Table 93. Fresenius Kabi Business Overview
Table 94. Fresenius Kabi Malignant Mesothelioma Therapeutic Product
Table 95. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 96. Fresenius Kabi Recent Development
Table 97. Sun Pharmaceuticals Company Detail
Table 98. Sun Pharmaceuticals Business Overview
Table 99. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product
Table 100. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 101. Sun Pharmaceuticals Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2023 VS 2030
Figure 3. Pemetrexed Features
Figure 4. Cisplatin Features
Figure 5. Others Features
Figure 6. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2023 VS 2030
Figure 8. Pleural Mesothelioma Case Studies
Figure 9. Peritoneal Mesothelioma Case Studies
Figure 10. Others Case Studies
Figure 11. Malignant Mesothelioma Therapeutic Report Years Considered
Figure 12. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2023 VS 2030
Figure 15. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2023
Figure 16. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2023
Figure 18. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 20. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 24. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Region (2019-2030)
Figure 32. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 40. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 44. Turkey Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 47. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 48. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 51. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 52. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 53. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 54. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 55. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 56. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Pemetrexed
Table 3. Key Players of Cisplatin
Table 4. Key Players of Others
Table 5. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Malignant Mesothelioma Therapeutic Market Share by Region (2019-2024)
Table 9. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Malignant Mesothelioma Therapeutic Market Share by Region (2025-2030)
Table 11. Malignant Mesothelioma Therapeutic Market Trends
Table 12. Malignant Mesothelioma Therapeutic Market Drivers
Table 13. Malignant Mesothelioma Therapeutic Market Challenges
Table 14. Malignant Mesothelioma Therapeutic Market Restraints
Table 15. Global Malignant Mesothelioma Therapeutic Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Malignant Mesothelioma Therapeutic Market Share by Players (2019-2024)
Table 17. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)
Table 18. Ranking of Global Top Malignant Mesothelioma Therapeutic Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
Table 22. Date of Enter into Malignant Mesothelioma Therapeutic Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2024)
Table 26. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2025-2030)
Table 28. Global Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2019-2024)
Table 30. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2025-2030)
Table 32. North America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 47. Eli Lilly Company Detail
Table 48. Eli Lilly Business Overview
Table 49. Eli Lilly Malignant Mesothelioma Therapeutic Product
Table 50. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 51. Eli Lilly Recent Development
Table 52. Teva Company Detail
Table 53. Teva Business Overview
Table 54. Teva Malignant Mesothelioma Therapeutic Product
Table 55. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 56. Teva Recent Development
Table 57. Sanofi Company Detail
Table 58. Sanofi Business Overview
Table 59. Sanofi Malignant Mesothelioma Therapeutic Product
Table 60. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 61. Sanofi Recent Development
Table 62. Bristol-Myers Squibb Company Detail
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product
Table 65. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Malignant Mesothelioma Therapeutic Product
Table 70. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Roche Company Detail
Table 73. Roche Business Overview
Table 74. Roche Malignant Mesothelioma Therapeutic Product
Table 75. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 76. Roche Recent Development
Table 77. Merck Company Detail
Table 78. Merck Business Overview
Table 79. Merck Malignant Mesothelioma Therapeutic Product
Table 80. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 81. Merck Recent Development
Table 82. Ono Pharmaceutical Company Detail
Table 83. Ono Pharmaceutical Business Overview
Table 84. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product
Table 85. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 86. Ono Pharmaceutical Recent Development
Table 87. Mylan Company Detail
Table 88. Mylan Business Overview
Table 89. Mylan Malignant Mesothelioma Therapeutic Product
Table 90. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 91. Mylan Recent Development
Table 92. Fresenius Kabi Company Detail
Table 93. Fresenius Kabi Business Overview
Table 94. Fresenius Kabi Malignant Mesothelioma Therapeutic Product
Table 95. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 96. Fresenius Kabi Recent Development
Table 97. Sun Pharmaceuticals Company Detail
Table 98. Sun Pharmaceuticals Business Overview
Table 99. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product
Table 100. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)
Table 101. Sun Pharmaceuticals Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2023 VS 2030
Figure 3. Pemetrexed Features
Figure 4. Cisplatin Features
Figure 5. Others Features
Figure 6. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2023 VS 2030
Figure 8. Pleural Mesothelioma Case Studies
Figure 9. Peritoneal Mesothelioma Case Studies
Figure 10. Others Case Studies
Figure 11. Malignant Mesothelioma Therapeutic Report Years Considered
Figure 12. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2023 VS 2030
Figure 15. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2023
Figure 16. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2023
Figure 18. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 20. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 24. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Region (2019-2030)
Figure 32. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 40. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)
Figure 44. Turkey Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 47. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 48. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 51. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 52. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 53. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 54. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 55. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 56. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232